Get started
Author

Mariamena Arbitrio

Observed names: Arbitrio, M, Arbitrio, Mariamena, M ARBITRIO, M Arbitrio, M. ARBITRIO, M. Arbitrio
Observed institutions: National Agency for New Technologies, Energy and Sustainable Economic Development, University of Rome Tor Vergata, National Academies of Sciences, Engineering, and Medicine, San Raffaele University of Rome, Magna Graecia University, Institute of Neurological Sciences, National Research Council, Institute for Biomedical Research and Innovation, Azienda Ospedaliero-Universitaria "Renato Dulbecco", National Research Council, ENEA Casaccia Research Centre, IRCCS San Raffaele Roma
ORCID: 0000-0001-8387-3664
Observed ORCID: 0000-0001-8387-3664
OpenAlex ID: A5074527116
The State of The Art on Acetylcholinesterase Inhibitors in the Treatment of Alzheimer’s Disease
2021 · Immacolata Vecchio, Luca Sorrentino, et al. · Journal of Central Nervous System Disease · 182
PDF
miR-221/222 as biomarkers and targets for therapeutic intervention on cancer and other diseases: A systematic review
2022 · Maria Teresa Di Martino, Mariamena Arbitrio, et al. · Molecular Therapy — Nucleic Acids · 150
PDF
Nanoparticle Albumin Bound Paclitaxel in the Treatment of Human Cancer: Nanodelivery Reaches Prime-Time?
2013 · Iole Cucinotto, Lucia Fiorillo, et al. · Journal of Drug Delivery · 102
Inhibition of miR-21 restores RANKL/OPG ratio in multiple myeloma-derived bone marrow stromal cells and impairs the resorbing activity of mature osteoclasts
2015 · Maria Rita Pitari, Marco Rossi, et al. · Oncotarget · 98
Single nucleotide polymorphisms of ABCC5 and ABCG1 transporter genes correlate to irinotecan-associated gastrointestinal toxicity in colorectal cancer patients: A DMET microarray profiling study
2011 · Maria Teresa Di Martino, Mariamena Arbitrio, et al. · Cancer Biology & Therapy · 95
PDF
miRNAs and lncRNAs as Novel Therapeutic Targets to Improve Cancer Immunotherapy
2021 · Maria Teresa Di Martino, Caterina Riillo, et al. · Cancers · 92
PDF
DMET™ (Drug Metabolism Enzymes and Transporters): a pharmacogenomic platform for precision medicine
2016 · Mariamena Arbitrio, Maria Teresa Di Martino, et al. · Oncotarget · 87
PDF
Safety and activity of the first-in-class locked nucleic acid (LNA) miR-221 selective inhibitor in refractory advanced cancer patients: a first-in-human, phase 1, open-label, dose-escalation study
2023 · Pierfrancesco Tassone, Maria Teresa Di Martino, et al. · Journal of Hematology & Oncology · 85
PDF
Pharmacogenomics Biomarker Discovery and Validation for Translation in Clinical Practice
2020 · Mariamena Arbitrio, Francesca Scionti, et al. · Clinical and Translational Science · 83
PDF
DMET-Analyzer: automatic analysis of Affymetrix DMET Data
2012 · Pietro Hiram Guzzi, Giuseppe Agapito, et al. · BMC Bioinformatics · 77
PDF
A peroxisome proliferator‐activated receptor gamma (PPARG) polymorphism is associated with zoledronic acid‐related osteonecrosis of the jaw in multiple myeloma patients: analysis by DMET microarray profiling
2011 · Maria T. Di Martino, Mariamena Arbitrio, et al. · British Journal of Haematology · 73
PDF
Inhibition of EZH2 triggers the tumor suppressive miR-29b network in multiple myeloma
2017 · Maria Angelica Stamato, Giada Juli, et al. · Oncotarget · 72
From Single Level Analysis to Multi-Omics Integrative Approaches: A Powerful Strategy towards the Precision Oncology
2018 · Maria Eugenia Gallo Cantafio, Katia Grillone, et al. · Microarrays · 66
PDF
In vivo anti‐myeloma activity and modulation of gene expression profile induced by valproic acid, a histone deacetylase inhibitor
2008 · Paola Neri, Pierosandro Tagliaferri, et al. · British Journal of Haematology · 63
PDF
Pharmacogenomic Profiling of ADME Gene Variants: Current Challenges and Validation Perspectives
2018 · Mariamena Arbitrio, Maria Teresa Di Martino, et al. · Microarrays · 62
PDF
Pharmacokinetics and Pharmacodynamics of a 13-mer LNA-inhibitor-miR-221 in Mice and Non-human Primates
2016 · Maria Eugenia Gallo Cantafio, Boye Schnack Nielsen, et al. · Molecular Therapy — Nucleic Acids · 60
PDF
miR-22 suppresses DNA ligase III addiction in multiple myeloma
2018 · Daniele Caracciolo, Maria Teresa Di Martino, et al. · Leukemia · 59
PDF
Exploiting MYC-induced PARPness to target genomic instability in multiple myeloma
2020 · Daniele Caracciolo, Francesca Scionti, et al. · Haematologica · 50
PDF
miR-21 antagonism abrogates Th17 tumor promoting functions in multiple myeloma
2020 · Marco Rossi, Emanuela Altomare, et al. · Leukemia · 47
Identification of polymorphic variants associated with erlotinib-related skin toxicity in advanced non-small cell lung cancer patients by DMET microarray analysis
2015 · Mariamena Arbitrio, Maria Teresa Di Martino, et al. · Cancer Chemotherapy and Pharmacology · 46
Mouse models of multiple myeloma: technologic platforms and perspectives
2018 · Marco Rossi, Cirino Botta, et al. · Oncotarget · 44
PDF
Trabectedin triggers direct and NK-mediated cytotoxicity in multiple myeloma
2019 · Maria Cucè, Maria Eugenia Gallo Cantafio, et al. · Journal of Hematology & Oncology · 41
PDF
Genetic variants associated with Fabry disease progression despite enzyme replacement therapy
2017 · Francesca Scionti, Maria Teresa Di Martino, et al. · Oncotarget · 41
PDF
The New Microtubule-Targeting Agent SIX2G Induces Immunogenic Cell Death in Multiple Myeloma
2022 · Katia Grillone, Caterina Riillo, et al. · International Journal of Molecular Sciences · 37
PDF
Genetic variants associated with gastrointestinal symptoms in Fabry disease
2016 · Maria Teresa Di Martino, Francesca Scionti, et al. · Oncotarget · 36
Works count: 120
Citation count: 2,489
H-index: 28
I10-index: 51
Year
Topic
Type